Phosphorylation of p38 MAPK mediates hypoxic preconditioning-induced neuroprotection against cerebral ischemic injury via mitochondria translocation of Bcl-xL in mice

Brain Res. 2013 Mar 29:1503:78-88. doi: 10.1016/j.brainres.2013.01.051. Epub 2013 Feb 8.

Abstract

Hypoxic preconditioning (HPC) initiates intracellular signaling pathway to provide protection, but the role of p38 mitogen-activated protein kinase (p38 MAPK) in HPC-induced neuroprotection against cerebral ischemic injuries is a matter of debate. In this study, we found that HPC could reduce 6h middle cerebral artery occlusion (MCAO)-induced infarct volume, edema ratio and cell apoptosis, as well as enhancing the up-regulated p38 MAPK phosphorylation (P-p38 MAPK) levels in the peri-infarct region of mice after 6h MCAO. However, intracerebroventricular injection of p38 MAPK inhibitor SB203580 abolished this HPC-induced neuroprotection. HPC significantly increased the translocation of anti-apoptotic Bcl-2-related protein Bcl-xL from the cytosol to the mitochondria in the peri-infarct region of MCAO mice. Interestingly, the results of reciprocal immunoprecipitation showed that Bcl-xL and P-p38 MAPK were coimmunoprecipitated reciprocally only in the peri-infarct region of HPC and MCAO treated mice, while Bcl-xL and total p38 (T-p38 MAPK), not P-p38 MAPK, could be coimmunoprecipited by each other in the brain of normal control mice. In addition, we found SB203580 significantly decreased P-p38 MAPK levels, and inhibited HPC-induced mitochondria translocation of Bcl-xL in the brain of HPC and MCAO treated mice. Taken together, our findings suggested that P-p38 MAPK mediates HPC-induced neuroprotection against cerebral ischemic injury via mitochondria translocation of Bcl-xL, which might be a key anti-cell apoptotic mechanism of HPC.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain Edema / etiology
  • Brain Edema / prevention & control
  • Brain Infarction / etiology
  • Brain Infarction / prevention & control
  • Disease Models, Animal
  • Enzyme Inhibitors / pharmacology
  • Imidazoles / pharmacology
  • Immunoprecipitation
  • In Situ Nick-End Labeling
  • Infarction, Middle Cerebral Artery / complications
  • Infarction, Middle Cerebral Artery / enzymology*
  • Infarction, Middle Cerebral Artery / prevention & control*
  • Ischemic Preconditioning / methods*
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Mitochondria / metabolism*
  • Phosphorylation / physiology
  • Protein Transport / physiology
  • Pyridines / pharmacology
  • Time Factors
  • bcl-X Protein / metabolism*
  • p38 Mitogen-Activated Protein Kinases / metabolism*

Substances

  • Enzyme Inhibitors
  • Imidazoles
  • Pyridines
  • bcl-X Protein
  • p38 Mitogen-Activated Protein Kinases
  • SB 203580